NCT05740696 Registry Study for Optimal Management of Liver Failure in the Chinese Population
| NCT ID | NCT05740696 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University |
| Condition | Liver Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-01-06 |
| Primary Completion | 2024-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2023-01-06 with a primary completion date of 2024-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Liver failure is the most severe form of liver damage caused by viral, alcoholic, drug-related and ischemia-reperfusion factors, often combined with extrahepatic organ damage, resulting in a high mortality rate. This study intends to construct a real-world case registry database of inpatients with liver failure based on an electronic clinical data collection system through a multicenter collaborative network to study the clinical characteristics, epidemiology of bacterial and fungal infections, the impact of sarcopenia on clinical prognosis, and optimization of treatment strategies such as antiviral and artificial liver in Chinese inpatients with liver failure. The cohort and experience generated from this study will be used as a support for a series of future studies to focus on clinical issues such as infection, end-stage liver disease combined with organ failure, and early warning of critically ill patients.
Eligibility Criteria
Inclusion Criteria: Patients with a diagnosis consistent with liver failure and pre-liver failure: * Extreme weakness with significant gastrointestinal symptoms such as anorexia, vomiting and abdominal distention; * Elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) with progressive jaundice (TBil≥85.5 μmol/L); * Bleeding tendency with PTA ≤ 60% or INR ≥ 1.5. Exclusion Criteria: * An event or complication that, in the judgment of the investigator, significantly affects the assessment of clinical status.
Contact & Investigator
Yingli He, Pro.
STUDY DIRECTOR
First Affiliated Hospital Xi'an Jiaotong University
Frequently Asked Questions
Who can join the NCT05740696 clinical trial?
This trial is open to participants of all sexes, studying Liver Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05740696 currently recruiting?
Yes, NCT05740696 is actively recruiting participants. Contact the research team at heyingli2000@xjtu.edu.cn for enrollment information.
Where is the NCT05740696 trial being conducted?
This trial is being conducted at Xi'an, China, Ankang, China, Changsha, China, Hanzhong, China and 10 additional locations.
Who is sponsoring the NCT05740696 clinical trial?
NCT05740696 is sponsored by First Affiliated Hospital Xi'an Jiaotong University. The principal investigator is Yingli He, Pro. at First Affiliated Hospital Xi'an Jiaotong University. The trial plans to enroll 500 participants.